Compare Dishman Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC PHARMA DISHMAN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 25.1 17.7 141.9% View Chart
P/BV x 3.3 7.0 47.6% View Chart
Dividend Yield % 0.7 0.5 122.5%  

Financials

 DISHMAN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA
Mar-19
DISHMAN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs374664 56.4%   
Low Rs129412 31.3%   
Sales per share (Unadj.) Rs197.8208.7 94.8%  
Earnings per share (Unadj.) Rs21.231.0 68.4%  
Cash flow per share (Unadj.) Rs34.737.1 93.6%  
Dividends per share (Unadj.) Rs2.005.50 36.4%  
Dividend yield (eoy) %0.81.0 77.8%  
Book value per share (Unadj.) Rs179.9144.2 124.7%  
Shares outstanding (eoy) m80.69188.52 42.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.6 49.3%   
Avg P/E ratio x11.917.4 68.3%  
P/CF ratio (eoy) x7.214.5 50.0%  
Price / Book Value ratio x1.43.7 37.5%  
Dividend payout %9.417.7 53.2%   
Avg Mkt Cap Rs m20,306101,461 20.0%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3557,467 71.7%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96139,347 40.6%  
Other income Rs m26594 282.9%   
Total revenues Rs m16,22639,441 41.1%   
Gross profit Rs m4,1038,736 47.0%  
Depreciation Rs m1,0911,152 94.6%   
Interest Rs m944184 513.0%   
Profit before tax Rs m2,3347,493 31.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-93 -1.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,568 39.8%   
Profit after tax Rs m1,7115,844 29.3%  
Gross profit margin %25.722.2 115.8%  
Effective tax rate %26.720.9 127.7%   
Net profit margin %10.714.9 72.2%  
BALANCE SHEET DATA
Current assets Rs m11,01819,577 56.3%   
Current liabilities Rs m9,51714,896 63.9%   
Net working cap to sales %9.411.9 79.0%  
Current ratio x1.21.3 88.1%  
Inventory Days Days11090 123.1%  
Debtors Days Days3545 76.8%  
Net fixed assets Rs m16,30427,097 60.2%   
Share capital Rs m161377 42.8%   
"Free" reserves Rs m12,90726,811 48.1%   
Net worth Rs m14,51627,188 53.4%   
Long term debt Rs m4,1894,993 83.9%   
Total assets Rs m29,80547,778 62.4%  
Interest coverage x3.541.7 8.3%   
Debt to equity ratio x0.30.2 157.2%  
Sales to assets ratio x0.50.8 65.0%   
Return on assets %8.912.6 70.6%  
Return on equity %11.821.5 54.8%  
Return on capital %17.523.6 74.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95219,453 25.5%   
Fx outflow Rs m6976,065 11.5%   
Net fx Rs m4,25513,388 31.8%   
CASH FLOW
From Operations Rs m2,7868,120 34.3%  
From Investments Rs m-1,529-7,556 20.2%  
From Financial Activity Rs m-941590 -159.4%  
Net Cashflow Rs m3161,153 27.4%  

Share Holding

Indian Promoters % 61.4 74.1 82.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.9 127.6%  
FIIs % 12.7 9.1 139.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 13.9 159.0%  
Shareholders   46,261 49,328 93.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NATCO PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  TORRENT PHARMA  BIOCON   

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Dives Over 1,100 Points, Dow Futures Down by 119 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS